louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05261438: Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Official title: Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-squamous NSCLC
Lead sponsor: Hunan Province Tumor Hospital
Sponsor class: OTHER
First posted: 2022-03-02
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Advanced Metastatic Non-squamous Non-small Cell Lung Cancer

Brief summary: This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Detailed description: This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Eligibility criteria: Inclusion Criteria:

18，Advanced Metastatic Non-squamous NSCLC Treatment Plan is atezolizumab-bevacizumab-carboplatin-paclitaxel

Exclusion Criteria:

Patients with contraindication of chemotherapy Pregnant or breast feeding women

Primary outcomes:
measure: OS
timeFrame: September 2019- september 2021
measure: PFS
timeFrame: September 2019- september 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Changsha
country: China
facility: Hunan Cancer Hospital
state: Hunan
Study officials:
affiliation: Hunan Cancer Hospital
name: Yongchang Zhang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02283138: Prediction of Neonatal Respiratory Distress Syndrome in Preterm Fetuses by Assessment of Fetal Lung Volume by Vocal and Pulmonary Artery Resistance Index a Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fetal Lung Volume of Preterm Fetuses Measured by VOCAL, PA-RI Measured by Pulsed Doppler
Keywords: FLV, VOCAL, PA-RI, preterm fetuses, RDS
Lead sponsor: Ain Shams University
Sponsor class: OTHER
Collaborators: name: Ain Shams Maternity Hospital
First posted: 2014-11-05
Enrollment: 60
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pregnant women at 28 to 34 weeks gestation

Brief summary: The investigators will measure fetal lung volume by VOCAL and pulmonary artery resistance index in preterm fetuses and correlating the results with postnatal respiratory distress of the preterm neonates.


Eligibility criteria: Inclusion Criteria:

* preterm labour

Exclusion Criteria:

* twins

Primary outcomes:
measure: Neonatal respiratory distress
timeFrame: at time of delivery
Secondary outcomes:
measure: Neonatal mortality rate
timeFrame: One week after delivery
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams Maternity Hospital
Study officials:
References:
Clinical trial NCT01325038: Effects of Increased Muscle Mass on Resting Metabolic Rate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Subjects
Keywords: resting metabolic rate
Lead sponsor: University Hospital, Linkoeping
Sponsor class: OTHER
First posted: 2011-03-29
Enrollment: 24
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Healthy males are randomized to isometric exercise for three months with either extra protein or extra calories in the form of a fast food meal/day in order to study if increase in muscle mass increases resting metabolic rate and if this is affected by presumed increased caloric intake as compared with only proteins.

Body-composition was measured with Dual-Energy X-ray Absorbimetry (DEXA) and RMR was measured by registration of CO2 production and O2 consumption.


Eligibility criteria: Inclusion Criteria:

* healthy males

Exclusion Criteria:

* significant disease
* inability to exercise

Primary outcomes:
measure: change in resting metabolic rate
timeFrame: 3 months
Secondary outcomes:
measure: change in muscle mass
timeFrame: 3 months
Other outcomes:
Locations:
city: Linkoping
country: Sweden
facility: University Hospital of Linkoping
Study officials:
References:
citation: Hambre D, Vergara M, Lood Y, Bachrach-Lindstrom M, Lindstrom T, Nystrom FH. A randomized trial of protein supplementation compared with extra fast food on the effects of resistance training to increase metabolism. Scand J Clin Lab Invest. 2012 Oct;72(6):471-8. doi: 10.3109/00365513.2012.698021. Epub 2012 Aug 30.
Clinical trial NCT05689138: Using Digestive Microbial Information to Enhance the Early Detection of Pancreatic Cancer
Official title: SCREENING ORAL AND GUT MICROBES AS A MORE ACCURATE NON-INVASIVE TOOL FOR PANCREATIC CANCER EARLY DETECTION: A POPULATION-BASED CASE-CONTROL STUDY IN CHINA
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pancreatic Cancer
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2023-01-18
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Present/ past diagnosis of (a) other malignancy, (b) infectious diseases, (c) oral or digestive diseases, (d) mental psychiatric or neurodegenerative diseases, (e) chronic diseases that may affect the organ function; Have received certain medical examinations or interventions within specific periods, including (a) antibiotics, hormonotherapy, or immunosuppressor in the past three months, (b) digestive tract reconstructive operation in the past three months, (c) Frequent use of a cathartic, antidiarrheal, or therapeutic dose of probiotics throughout the past one month, (d) Change of diet throughout the past one month, (e) local antibiotics usage in 1 week(skin, antibacterial mouth wash) (f) oral or digestive examination in 3 days.

Brief summary: Pancreatic cancer (PCA) is a leading death-related cancer. There is an urgent need for accurate, noninvasive diagnostic options in the early detection of pancreatic cancer (PCA), since delayed diagnosis increases the risk of metastasis and recurrence. In this study, by analyzing gut and fecal microbial data among the pancreatic versus healthy populations, we aim to establish an early detection tool to improve PCA detection, and to explore potential diagnostic biomarkers.


Eligibility criteria: Inclusion Criteria:

PCA Newly diagnosed pancreatic cancer patients; No symptoms of jaundice; Did not yet receive any treatment

NC Individuals who were undergoing routine screenings or physical examination

Exclusion Criteria:

Primary outcomes:
measure: microbial features by 16s rRNA sequencing
timeFrame: within 180 days
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: PUMCH
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Menghua Dai, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03063008: Transforaminal Lumbar Interbody Fusion in PEEK Oblique Cages With and Without Titanium Coating
Official title: "Randomized Evaluation of Bone Ingrowth After Intervertebral Body Fusion With Either MectaLIF® PEEK or MectaLIF® TiPEEK Oblique"
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vertebral Fusion
Keywords: Lumbar spine; Fusion; Titanium; PEEK
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2017-02-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical outcome with regard to oswestry disability index and lumbar fusion rate after implantation of titanium coated PEEK cage and common PEEK cage

Detailed description: Cages made of polyetheretherketone (PEEK) and titanium materials reliably produce successful fusion rates and good clinical outcomes. However, there is a paucity of studies that have assessed the optimal material of cage systems. The primary objective of this study was to compare the Oswestry Disability Index (ODI) after instrumented transforaminal lumbar interbody fusion (TLIF) using either titanium-coated polyetheretherketone (TiPEEK) or common PEEK cages. Secondary objectives were to assess differences in fusion rates and differences in pain and in quality of life between these groups.

Eligibility criteria: Inclusion Criteria:

Persistence of

* low back pain,
* sciatica and
* spinal claudication after conservative treatment attributed to L3 to L5 lumbar segments.

Exclusion Criteria:

* previous lumbar spinal surgery
* body mass index \>35 kg/m²

Primary outcomes:
measure: Clinical outcome assessed by Oswestry Disability Index (ODI) after instrumented transforaminal lumbar fusion with TiPEEK or common PEEK
timeFrame: 12 months
Secondary outcomes:
measure: Fusion result
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
affiliation: Department of Orthopedic Surgery, University Hospital Frankfurt
name: Mohammad Arabmotlagh, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01508208: Comparison of Urine Protein/Creatinine Ratio With 24-hour Urine Protein Excretion in Woman With Hypertensive Disorders
Official title: A Comparison of Spot Test (Urine Protein/Creatinine Ratio) With 24 - Hour Urine Protein Excretion in Woman With Hypertensive Disorders of Pregnancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension, Pregnancy-Induced
Keywords: Hypertension
24 hour urine protein
Protein/creatinine ratio
Lead sponsor: Saint Thomas Hospital, Panama
Sponsor class: OTHER
First posted: 2012-01-11
Enrollment: 420
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The presence of proteinuria (\>300 mg/d) represents an important factor in the diagnosis and evaluation of the pregnant patient with an hypertensive disorder. The 24 hour collection of urine for proteinuria is the gold standard for the diagnosis of the condition and allows the physician to determine if an hypertensive disorder is related directly or not to the gestation.

The problem is the time it takes and the technical difficulties related to the sample collection. An alternative is the quantification of protein and creatinine in a random sample of urine. We seek to evaluate if this method is as affective as the gold standard in the diagnosis of proteinuria (\>300 mg/d).


Eligibility criteria: Inclusion Criteria:

* Pregnant women with 28 weeks or more of gestation.
* Complete collection of the 24 hour urine sample.

Exclusion Criteria:

* Failure to recollect the 24 hour urine sample.
* Pregestational Diabetes
* Kidney disease
* 24 hour urine protein \> 8.0 g/dL or seric creatinine \> 2.0 mg/dL (it could indicate kidney disease).

Primary outcomes:
measure: Sensitivity and Specificity
timeFrame: Six months
Secondary outcomes:
measure: Positive and Negative Predictive Value
timeFrame: six months
Other outcomes:
Locations:
city: Panama
country: Panama
facility: Saint Thomas H
Study officials:
affiliation: Saint Thomas Hospital, Panama
name: Osvaldo A Reyes, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Saint Thomas Hospital, Panama
name: Joanna Buitrago, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00221208: Home Based Resistance Training For Type 2 Diabetes
Official title: A Home Based Resistance Training Program for Obese Adults With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes
Keywords: Diabetes
Resistance Training
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2005-09-22
Enrollment: 54
Sex: ALL
Minimum age (years): 25
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will investigate the biological and psychosocial benefits of a home-based resistance-training program for sedentary, obese adults living with type 2 diabetes.

Detailed description: Obese individuals with type 2 diabetes will be randomly assigned to either an experimental group where they will perform moderate to high intensity resistance training (50-60% 1RM weeks 1-3 and 70-85% 1RM in weeks 4-16) three times per week for 16 weeks or to a non-training control group. All resistance training will be performed at home using a multigym apparatus. A personal trainer (PT) will come to the homes of each participant in the experimental group to make sure that exercises are being performed safely with the correct technique, and at the prescribed intensity. In the first two weeks, the PT will come to all 3 sessions per week. In weeks 3-4 this will be reduced to 2 times per week, in weeks 5-8 the PT will come once per week and in the last 8 weeks once bi-weekly.

Eligibility criteria: Inclusion Criteria:

Type 2 Diabetes Overweight and Obese (BMI\>28) Living inside of City limits

Exclusion Criteria:

Ischemic heart disease Osteoporosis Musculoskeletal abnormalities Currently performing resistance training

Primary outcomes:
measure: HbA1c
measure: Muscular strength
Secondary outcomes:
measure: Fasting blood glucose, insulin, lipid concentrations, C-reactive protein, body composition (DEXA), exercise adherence, behaviour change, psychosocial predictors of resistance training, quality of life.
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
Study officials:
affiliation: University of Alberta
name: Ron C Plotnikoff, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Plotnikoff RC, Eves N, Jung M, Sigal RJ, Padwal R, Karunamuni N. Multicomponent, home-based resistance training for obese adults with type 2 diabetes: a randomized controlled trial. Int J Obes (Lond). 2010 Dec;34(12):1733-41. doi: 10.1038/ijo.2010.109. Epub 2010 Jun 8.
Clinical trial NCT04490408: Surgical Bypass Versus Hybrid Approaches for Critical Limb Ischemia
Official title: Long Surgical Bypass Versus Hybrid Approaches for Management of Critical Limb Ischemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Critical Lower Limb Ischemia
Lead sponsor: Egyptian Biomedical Research Network
Sponsor class: NETWORK
First posted: 2020-07-29
Enrollment: 52
Sex: ALL
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present randomized study proposed to compare the immediate postoperative and 2-year clinical outcomes of long surgical bypass and hybrid approaches in patients with multilevel critical lower limb ischemia.


Eligibility criteria: Inclusion Criteria:

* TASC II type D femoropopliteal lesions with intact ipsilateral femoral pulse.
* Fontaine classification stage IV (gangrene or necrosis).
* Rutherford grade III and IV category 5 and 6 with salvageable foot

Exclusion Criteria:

* heart failure
* liver failure
* renal impairment

Primary outcomes:
measure: Late occlusion
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00790608: Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA)
Official title: A Phase II Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus in MRSA Positive Ulcers
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Skin Ulcers
Methicillin-resistant Staphylococcus Aureus Infection
Lead sponsor: Nitric BioTherapeutics, Inc
Sponsor class: INDUSTRY
First posted: 2008-11-13
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine if topically applied nitric oxide gas is effective in reducing the quantity of bacteria (including MRSA)in a wound.


Eligibility criteria: Inclusion Criteria:

* Must have given written informed consent
* Must be ≥ 18 years of age and not of child bearing potential
* Must have an ulcer in which the presence of MRSA has been identified, but which is not clinically infected
* Must have an ulcer size not to extend beyond the inner borders of the dressing

Exclusion Criteria:

* Is a female of child bearing years or who could become pregnant
* Is \< 18 years of age
* Has an clinically infected skin ulcer
* Has a ulcer that is being treated with a topical antimicrobial agent or has been treated with a topical antimicrobial agent during 3 days prior to enrolment
* Has been using systemic antibiotics during 7 days prior to enrolment into this study
* Has an ulcer which is identified as malignant in origin (e.g. Marjolin's ulcer)
* Has an ulcer size beyond the inner borders of the dressing
* Is septic or has other signs of an invasive infection
* Has used any investigational drug within 30 days preceding study participation.
* Suffers from a condition, which, in the opinion of the Investigator, would compromise his or her safety.
* Suffers from a condition which, in the opinion of the Investigator, would compromise the quality of the data.
* Has a known allergy to any of the products that are part of this protocol
* Suffers from a condition which, in the opinion of the Investigator, would seriously interfere negatively with the normal parameters of immune response to an infection.
* Is using any of the prohibited concomitant medications or treatments

Primary outcomes:
measure: Change in bioburden (specifically MRSA)as assessed via quantitative cultures.
timeFrame: 10 Days
Secondary outcomes:
measure: Improvement in the condition of the ulcer as judged by comparative photography and independent clinical assessment
timeFrame: 10 Days
measure: Incidence of adverse events
timeFrame: 10 Days
Other outcomes:
Locations:
city: Cardiff
country: United Kingdom
facility: Department of Wound Healing, Cardiff University
Study officials:
affiliation: Department of Wound Healing, Cardiff University
name: Keith Harding, MB ChB, MRGCP, FRCS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04886908: Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology
Official title: Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Skin Cancer
Lead sponsor: Brugmann University Hospital
Sponsor class: OTHER
First posted: 2021-05-14
Enrollment: 373
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Identification of all patients who have undergone surgical excision of benign or malignant facial and/or eyelid tumors over the past 5 years in the Dermatology and/or Ophthalmology Departments of the CHU Saint-Pierre and CHU Brugmann hospitals.

Brief summary: Skin cancers are the most common of all cancers. Their incidence has increased sharply over the decades.This increase in incidence partly reflects an aging population and behavioral patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop in photo-exposed regions such as the cephalic extremity.

The objective of this study is to provide an epidemiological analysis of tumors in the populations of both CHU Brugmann and St Pierre hospitals.


Eligibility criteria: Inclusion Criteria:

Final diagnosis confirmed by pathological analysis, epidemiological and clinical information available from patients.

Exclusion Criteria:

Patients who have expressed a refusal to access their medical file or incomplete data will not be taken into account.

Primary outcomes:
measure: Age
timeFrame: 5 minutes
measure: Sex
timeFrame: 5 minutes
measure: Name of the department in which the patient is followed
timeFrame: 5 minutes
measure: Tumor anatomical location
timeFrame: 5 minutes
measure: Tumor size
timeFrame: 5 minutes
measure: Laterality
timeFrame: 5 minutes
measure: Multiple or single tumor
timeFrame: 5 minutes
measure: Primitive tumor or recidive
timeFrame: 5 minutes
measure: Risk factor: phototype
timeFrame: 5 minutes
measure: Risk factor: immunosuppression (yes/no)
timeFrame: 5 minutes
measure: Risk factor: keratosis
timeFrame: 5 minutes
measure: Risk factor: solar exposition (yes/no)
timeFrame: 5 minutes
measure: Diagnosis
timeFrame: 5 minutes
measure: Locoregional extension report (yes/no)
timeFrame: 5 minutes
measure: Histological diagnosis of the tumor
timeFrame: 5 minutes
measure: Healthy or invaded margins
timeFrame: 5 minutes
measure: Superficial or infiltrating tumor
timeFrame: 5 minutes
measure: Diagnostic method
timeFrame: 5 minutes
measure: Surgical management method
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: CHU Brugmann
Study officials:
affiliation: CHU Brugmann
name: Nosria Boulakhrif
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04057508: Non-invasive Modulation of Autonomic Cardiac Nervous System
Official title: Effects of Non Invasive Vagus Nerve Stimulation on Heart Rate Variability in Healthy Subjects and on Muscle Sympathetic Nerve Activity
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Autonomic Nervous System
Heart Rate Variability
Muscle Sympathetic Nerve Activity
Keywords: Heart rate variability, MSNA, vagus nerve, sympathetic nervous system
Lead sponsor: Université Catholique de Louvain
Sponsor class: OTHER
Collaborators: name: Erasme University Hospital
First posted: 2019-08-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Randomized, controlled, double-blind, cross-over study
Primary purpose: BASIC_SCIENCE

Brief summary: To demonstrate the effect of non invasive vagus nerve (VNS) stimulation on heart rate variability and MSNA signal.

Detailed description: First part: Assessment of the muscle sympathetic nerve activity (MSNA) at baseline using microneurography performed on the superficial peroneal nerve.

Second part: Acquisition of the MSNA signal during non-invasive VNS and apnea. Non-invasive VNS is performed using several frequencies of stimulation. Maximal and voluntaries apnea are performed at the end of the expiration.

Continuous recording of the following parameters:

* non-invasive arterial blood pressure
* R-R interval
* electrocardiogram
* MSNA activity
* respiratory curve signal
* respiratory rate, oxygen saturation

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* \>18 years old

Exclusion Criteria:

* pregnancy and breastfeeding
* smoke
* alcool/energy drinks/coffee consumption, exertion 24h before the participation

Primary outcomes:
measure: Heart rate variability modulation
timeFrame: 4 hours
Secondary outcomes:
measure: Non-invasive vagus nerve stimulation
timeFrame: 4hours
measure: Profile of response for MSNA
timeFrame: 4 hours
Other outcomes:
measure: Profile of response of MSNA during prolonged breath hold
timeFrame: 4hours
Locations:
city: Brussels
country: Belgium
facility: Erasme University Hospital
Study officials:
References: